Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Duration: September 12, 2016
to
present
General Issues: Budget/Appropriations , Health Issues
Spending: about $470,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Health Resources & Services Administration (HRSA), Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on May 1.
Original Filing: 301577613.xml
Lobbying Issues
Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Feb. 6.
Original Filing: 301543527.xml
Lobbying Issues
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301515039.xml
Lobbying Issues
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 21, 2023.
Original Filing: 301492971.xml
Lobbying Issues
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301461997.xml
Lobbying Issues
Increases for funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC. Increases for funding for reproductive health programs at HRSA, USAID
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117) and reintroduction of the Black Maternal Health Momnibus. Urging FDA to take actions to ensure continued access to mifepristone.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301441592.xml
Lobbying Issues
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346); Advancing Safe Medications for Moms and Babies Act (HR 9487)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301419718.xml
Lobbying Issues
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346) programs
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 21, 2022.
Original Filing: 301396851.xml
Lobbying Issues
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 21, 2022.
Original Filing: 301372998.xml
Lobbying Issues
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Jan. 24, 2022.
Original Filing: 301339623.xml
Lobbying Issues
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 21, 2021.
Original Filing: 301315399.xml
Lobbying Issues
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/s 346) programs
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 7, 2021.
Original Filing: 301273979.xml
Lobbying Issues
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 7, 2021.
Original Filing: 301273976.xml
Lobbying Issues
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
Agencies Lobbied
U.S. Senate
Lobbying Issues
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Feb. 5, 2021.
Original Filing: 301247786.xml
Lobbying Issues
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301222927.xml
Lobbying Issues
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
SOCIETY FOR MATERNAL-FETAL MEDICINE filed a lobbying registration on July 20, 2020 for in-house lobbying efforts, effective May 26, 2020.
Original Filing: 301196974.xml
Issue(s) they said they’d lobby about: FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA
maternity care, research & pregnancy, maternal mental health .
2nd Quarter, 2020
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301197126.xml
Lobbying Issues
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 13, 2020.
Original Filing: 301165611.xml
Lobbying Issues
FY20 and FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
Black Maternal Health Momnibus; maternal mortality, severe maternal morbidity, research in pregnancy; Healthy Start; FY21 Labor-HHS-Education appropriations
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Feb. 11, 2020.
Original Filing: 301131645.xml
Lobbying Issues
FY20 and FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 916/HR 1897 MOMMA's Act (maternal mortality); S. 116 MOMS Act (maternal health); HR 2902/ S 1600 Maternal CARE Act; HR 1551/S 1960 Quality Care for Moms and Babies Act; maternal mortality, severe maternal morbidity, research in pregnancy; Healthy Start
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 20, 2019.
Original Filing: 301072401.xml
Lobbying Issues
FY20 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 916/HR 1897 MOMMA's Act (maternal mortality); S. 116 MOMS Act (maternal health); HR 2902/ S 1600 Maternal CARE Act; HR 1551/S 1960 Quality Care for Moms and Babies Act; maternal mortality, severe maternal morbidity, research in pregnancy; Healthy Start
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 23, 2019.
Original Filing: 301059370.xml
Lobbying Issues
FY20 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 916/HR 1897 MOMMA's Act (maternal mortality); S. 116 MOMS Act (maternal health); HR 2902/ S 1600 Maternal CARE Act; HR 1551/S 1960 Quality Care for Moms and Babies Act; maternal mortality, severe maternal morbidity, research in pregnancy
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301033406.xml
Lobbying Issues
FY20 Labor-Health and Human Services-Education approporiations/maternal and infant health/AHRQ/NIH/CDC/HRSA
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 916/HR 1897 MOMMA's Act (maternal mortality); S. 116 MOMS Act (maternal health); maternal mortality, severe maternal morbidity, research in pregnancy
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Feb. 2, 2019.
Original Filing: 301019606.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2019, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health services; health services research; maternal mortality.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Preventing Maternal Deaths Act (HR 1318), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act (S. 2367/HR 5457), Improving Access to Maternity Care Act (S. 783, HR 315); PREEMIE Reauthorization (S. 3029/HR 6085); MOMMA's Act (HR 5977); Ending Maternal Mortality Act (HR 5761); pregnancy research.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 18, 2018.
Original Filing: 300989081.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2019, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health services; health services research; maternal mortality.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Preventing Maternal Deaths Act (HR 1318), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act (S. 2367/HR 5457), Improving Access to Maternity Care Act (S. 783, HR 315); PREEMIE Reauthorization (S. 3029/HR 6085); MOMMA's Act (HR 5977); Ending Maternal Mortality Act (HR 5761); pregnancy research.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300974026.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2019, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health services; health services research; maternal mortality.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Preventing Maternal Deaths Act (HR 1318), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act (S. 2367/HR 5457), Improving Access to Maternity Care Act (S. 783, HR 315); PREEMIE Reauthorization (S. 3029/HR 6085); MOMMA's Act (HR 5977); Ending Maternal Mortality Act (HR 5761); pregnancy research.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 23, 2018.
Original Filing: 300958666.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2018, Labor-HHS-Education Appropriations bill FY2019, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Preventing Maternal Deaths Act (HR 1318/), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act (S. 2367/HR 5457), Improving Access to Maternity Care Act (S. 783, HR 315); pregnancy research.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on March 9, 2018.
Original Filing: 300941157.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2018, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act, Best Care Reconciliation Act, Preventing Maternal Deaths Act (HR 1318/), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act, Improving Access to Maternity Care Act (S. 783, HR 315), Children's Health Insurance Program; prenatal screening, pregnancy research.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300912181.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; opioids; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act, Best Care Reconciliation Act, Preventing Maternal Deaths Act (HR 1318/), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act, Improving Access to Maternity Care Act (S. 783, HR 315), Children's Health Insurance Program; prenatal screening, pregnancy research.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300893898.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill, FDA funding, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act, Best Care Reconciliation Act, Preventing Maternal Deaths Act (HR 1318/), Maternal Health Accountability Act (S. 1112), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act, Improving Access to Maternity Care Act (S. 783, HR 315), prenatal screening, pregnancy research.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300873982.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill FY2017 and FY2018, maternal-fetal medicine research; sequestration and non-defense discretionary funding; maternal mental health; family planning/Title X; Zika; pre-term birth; pregnancy surveillance; reproductive health service; health services research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act, Preventing Maternal Deaths Act (HR 1318), pre-term birth, maternal mental health, Quality Care for Moms and Babies Act, Improving Access to Maternity Care Act (S. 783, HR 315).
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists. The report was filed on Jan. 22, 2017.
Original Filing: 300854388.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill, FY 2017, maternal-fetal medicine research; medications in pregnancy and breastfeeding; Zika; pre-term birth
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternity care, research & pregnancy, maternal mental health, S. 2311 Bringing Postpartum Depression Out of the Shadows Act, 21st Century Cures, Innovations for Healthier Americans, Quality Care for Moms and Babies Act, HR 3441 Accurate Education for Prenatal Screenings Act, HR 1209/S 628 Improving Access to Maternity Care Act, S 799/HR 1462 Protecting Our Infants Act, S 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act, HR 5219 Safe Medications for Moms and Babies Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
SOCIETY FOR MATERNAL-FETAL MEDICINE amended a lobbying report for in-house lobbying in Q32016 on Oct. 26, 2016
Original Filing: 300840876.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill, FY 2017, maternal-fetal medicine research; medications in pregnancy and breastfeeding; Zika; pre-term birth; family planning/Title X
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternity care, research & pregnancy, maternal mental health, S. 2311 Bringing Postpartum Depression Out of the Shadows Act, 21st Century Cures, Innovations for Healthier Americans, Quality Care for Moms and Babies Act, HR 3441 Accurate Education for Prenatal Screenings Act, HR 1209/S 628 Improving Access to Maternity Care Act, S 799/HR 1462 Protecting Our Infants Act, S 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act, HR 5219 Safe Medications for Moms and Babies Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, SOCIETY FOR MATERNAL-FETAL MEDICINE had in-house lobbyists, and was paid $20,000. The report was filed on Oct. 25, 2016.
Original Filing: 300840704.xml
Lobbying Issues
Labor-HHS-Education Appropriations bill, FY 2017, maternal-fetal medicine research; medications in pregnancy and breastfeeding; Zika; pre-term birth; family planning/Title X
Agencies Lobbied
U.S. Senate
Lobbying Issues
maternity care, research & pregnancy, maternal mental health, S. 2311 Bringing Postpartum Depression Out of the Shadows Act, 21st Century Cures, Innovations for Healthier Americans, Quality Care for Moms and Babies Act, HR 3441 Accurate Education for Prenatal Screenings Act, HR 1209/S 628 Improving Access to Maternity Care Act, S 799/HR 1462 Protecting Our Infants Act, S 2745 Advancing NIH Strategic Planning and Representation in Medical Research Act, HR 5219 Safe Medications for Moms and Babies Act
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...